Aktis Oncology (NASDAQ:AKTS) Upgraded to Strong-Buy at BMO Capital MarketsMarket Beat·Aug 20 at 06:06 AMAKTS+0.29%
The Hidden Corners of Capital: AI Pivots, Bankruptcies, and the Survival of the UncategorizedGlobal Report·Aug 18 at 05:12 AMGRPN-0.05%BHE-0.98%
Aktis Oncology (NASDAQ:AKTS) Posts Earnings Results, Meets ExpectationsMarket Beat·Aug 13 at 03:41 PMAKTS+0.29%
Market Misfits of 2026: Crypto Fines, Delisted Zombies, and Sneeze-Inducing ETFsGlobal Report·Aug 12 at 05:12 AMGRSD-2.00%LX-0.75%
Capital Rotates to Yield ETFs and Niche SPACs in Fragmented MarketGlobal Report·Aug 8 at 04:20 AMAKTS+0.29%BIXI0.00%
Has Aktis Oncology (AKTS) Fallen Far Enough To Be Below Fair Value?Simplywall·Jul 24 at 12:03 AMAKTS+0.29%
Aktis Oncology director Ken Herrmann disposes of common shares worth $119,256.78PUBT·Jul 21 at 07:51 PMAKTS+0.29%
Aktis Oncology Insider Makes Notable Move With Fresh Stock SaleTip Ranks·Jul 20 at 09:02 PMAKTS+0.29%
Aktis Oncology director Ken Herrmann disposes of 3,065 common shares worth $77,279.54PUBT·Jul 20 at 04:35 PMAKTS+0.29%
Aktis Oncology Initiated at Buy on AKY-1189’s Potential to Surpass Current Second-Line Bladder Cancer Chemotherapy BenchmarkTip Ranks·Jul 14 at 03:45 PMAKTS+0.29%
JPMorgan Chase & Co. Increases Aktis Oncology (NASDAQ:AKTS) Price Target to $33.00Market Beat·Jul 14 at 09:18 AMAKTS+0.29%
Aktis Oncology CMO Akos Czibere disposes of common shares worth $1.29 millionPUBT·Jul 10 at 05:11 AMAKTS+0.29%
